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Introduction 
• Bacterial resistance to antibiotics is increasing, but varies greatly in different geographical 
locations. 
• Antimicrobial use is considered the major factor driving this increase. 
• This study aims to assess urinary Escherichia coli susceptibility patterns in the Australian 
island-state of Tasmania, and explore their relationship with community antibiotic use. 
Methods 
• The susceptibility profiles of all urinary E. coli isolates between January 2010 and December 
2012 in Tasmania were included; this was a population-based study. 
• Susceptibility testing had been done using disc diffusion with CDS methodology1, with the 
exception of 2011 & 2012 isolates from one laboratory, which were tested using EUCAST 
methodology2. 
• Isolates were classified as either “susceptible” or “not susceptible” (intermediate or 
resistant) to each antibiotic tested. 
• Only the 1st isolate from each patient, each year was included in the analyses for 
geographical and temporal differences. 
• The number of PBS-subsidised prescriptions for amoxycillin, amoxycillin-clavulanate and 
cephalexin in Tasmania each month was downloaded from the PBS website3, and converted 
to defined daily doses (DDDs) per 1,000 population per day4,5.  This represents antibiotic 
use by concession card holders. 
Results 
• There were 42,691 isolates included in total; 32,920 isolates were included in the 
analyses for geographical and temporal differences. 
Geographical differences 
• Antimicrobial resistance levels were low and regional differences were small, 
although resistance to amoxycillin-clavulanate, cephalexin and norfloxacin was 
greater in the South than the North and Northwest of Tasmania (Table 1). 
Temporal changes 
• The proportion of E. coli isolates not susceptible to amoxycillin-clavulanate increased 
from 3.4% in 2010 to 4.2% in 2012 (P=0.01), but there was no increase in resistance 
to other antibiotics detected when analysed using linear regression. 
• There was an increase in the proportion of E. coli isolates not susceptible to 
amoxycillin from 34.2% during Summer/Autumn to 36.1% during Winter/Spring 
(P<0.01) (Figure 1). 
• Amoxycillin use increased from 2.07 DDDs per 1,000 population per day in 
Summer/Autumn to 2.79 in Winter/Spring (P<0.01)(Figure 1). 
• The results of logistic regression models further evaluating the effect of season and 
lag in resistance after antibiotic use are shown in Table 2. 
Recurrent isolates 
• 7,653 patients had E. coli isolated on multiple occasions during the study. 
• The proportion of E. coli isolates not susceptible to each antimicrobial tested 
increased with each episode (Figure 2). 
Conclusions 
• E. coli resistance to antimicrobials is lower in Tasmania than reported elsewhere in 
Australia, which may be due to Tasmania’s isolated geographical location. 
• There was no increase in antibiotic resistance detected during this 3-year study, with 
the exception of minimal increase in amoxycillin-clavulanate resistance. 
• An increase in amoxycillin use and resistance was identified during winter and 
spring, which may be due to treatment of respiratory tract infections. 
• Increased resistance to amoxycillin and amoxycillin-clavulanate was seen following a 
2-month lag after increased use of each of these antimicrobials. 
• The increase in antimicrobial resistance in recurrent isolates is likely to be a result of 
antimicrobial treatment in patients with recurrent urinary tract infection. 
Antibiotic 
Proportion Not Susceptible 
P-Value 
South  North Northwest 
Amoxycillin 35.7% 33.8% 35.6% <0.01 
Amoxycillin-
clavulanate 
4.6% 3.6% 2.2% <0.01 
Cephalexin 3.6% 3.4% 2.7% 0.01 
Gentamicin 1.9% 1.9% 1.4% 0.03 
Norfloxacin 4.0% 2.4% 1.7% <0.01 
Trimethoprim 14.7 % 13.5% 14.2% 0.03 
Figure 2. Antimicrobial resistance in recurrent E. coli isolates. 
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Table 1. Suseptibility profile of urinary E. coli isolates in 
Tasmania. 
Table 2. Logistic regression models* assessing season and lag in 
resistance after antimicrobial use. 
*Methods for Logistic Regression 
•Season was transformed from month of year (1 to 12), into a sine wave taking on values between -1 and +1, 
with the peak in July and nadir in January to represent anticipated increased risk associated with winter 
months.  
•The number of isolates not susceptible each month was assumed to have a binomial distribution determined 
by the proportion resistant and the number of isolates collected for the month.  
•The outcome variable was the proportion of isolates not susceptible to the antimicrobial each month. 
•Predictors assessed included time, season, antimicrobial use (DDDs per 1,000 population per day) in the 
same month, and antimicrobial use 1, 2 and 3 months prior. 
•Univariate and multivariate logistic regression models were created.  Only predictors with P≤0.1 were 
included in the final model. 
Figure 1. Amoxycillin use and E. coli resistance to amoxycillin. Odds Ratio 
Confidence 
Interval 
Outcome: Amoxycillin resistance 
Season (peak July) 1.17 1.09-1.26 
Amoxycillin use, 2-month lag 1.12 1.06-1.17 
Outcome: Amoxycillin-clavulanate resistance 
Amoxcycillin-clavulanate use, 
2-month lag 
1.26 1.04-1.52 
Amoxcycillin-clavulanate use,  
3-month lag 
1.17 0.97-1.40 
Outcome: Cephalexin resistance 
Season (peak July) 1.17 0.99-1.38 
